Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-14 10:45 am Sale | 2025-03-31 | 13G | MoonLake Immunotherapeutics MLTX | T. Rowe Price Associates, Inc. | 2,974,271 4.700% | -369,372 (-11.05%) | Filing History |
| 2025-02-14 09:44 am Purchase | 2024-12-31 | 13G | MoonLake Immunotherapeutics MLTX | T. Rowe Price Associates, Inc. | 3,343,643 5.300% | 2,521,042 (+306.47%) | Filing History |
| 2025-02-12 09:30 am Purchase | 2024-12-31 | 13G | MoonLake Immunotherapeutics MLTX | FMR LLC | 6,306,391 10.000% | 1,365,267 (+27.63%) | Filing History |
| 2024-11-12 10:32 am Purchase | 2024-11-08 | 13G | MoonLake Immunotherapeutics MLTX | FMR LLC | 4,941,124 7.856% | 1,093,447 (+28.42%) | Filing History |
| 2024-10-08 6:48 pm Sale | 2024-10-04 | 13D | MoonLake Immunotherapeutics MLTX | BIOTECHNOLOGY VALUE FUND L P | 19,751,284 31.400% | -2,000,000 (-9.19%) | Filing History |
| 2024-03-05 4:59 pm Unchanged | 2024-02-29 | 13D | MoonLake Immunotherapeutics MLTX | BIOTECHNOLOGY VALUE FUND L P | 21,751,284 34.600% | 0 (Unchanged) | Filing History |
| 2024-02-15 08:00 am Sale | 2023-12-31 | 13G | Helix Acquisition Corp. HLXA | Merck Healthcare KGaA | 2,787,509 4.700% | -542,722 (-16.30%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | MoonLake Immunotherapeutics MLTX | Citadel Advisors LLC | 2,034,260 3.400% | -851,832 (-29.52%) | Filing History |
| 2024-02-14 3:05 pm Purchase | 2023-12-31 | 13G | MoonLake Immunotherapeutics MLTX | Chen Bihua | 8,494,151 14.170% | 1,602,051 (+23.24%) | Filing History |
| 2024-02-09 09:28 am Purchase | 2024-02-08 | 13G | MoonLake Immunotherapeutics MLTX | FMR LLC | 3,847,677 6.419% | 2,654,677 (+222.52%) | Filing History |
| 2023-06-30 4:41 pm Unchanged | 2023-06-27 | 13D | MoonLake Immunotherapeutics MLTX | BIOTECHNOLOGY VALUE FUND L P | 21,751,284 35.800% | 0 (Unchanged) | Filing History |
| 2023-03-31 4:23 pm Purchase | 2022-12-31 | 13G | MoonLake Immunotherapeutics MLTX | Chen Bihua | 6,892,100 17.600% | 6,892,100 (New Position) | Filing History |
| 2023-02-14 12:38 pm Purchase | 2022-12-31 | 13G | MoonLake Immunotherapeutics MLTX | T. Rowe Price Associates, Inc. | 822,601 2.100% | 822,601 (New Position) | Filing History |
| 2023-02-14 08:26 am Purchase | 2022-12-31 | 13G | MoonLake Immunotherapeutics MLTX | Citadel Advisors LLC | 2,886,092 7.400% | 2,886,092 (New Position) | Filing History |
| 2023-02-09 12:48 pm Purchase | 2023-02-09 | 13G | MoonLake Immunotherapeutics MLTX | FMR LLC | 1,193,000 3.230% | 1,193,000 (New Position) | Filing History |
| 2023-02-09 10:09 am Unchanged | 2022-12-31 | 13G | MoonLake Immunotherapeutics MLTX | ADAGE CAPITAL PARTNERS GP L.L.C. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2023-01-27 06:13 am Purchase | 2022-12-31 | 13G | Helix Acquisition Corp. HLXA | Merck Healthcare KGaA | 3,330,231 7.900% | 3,330,231 (New Position) | Filing History |
| 2022-08-03 06:17 am Purchase | 2022-08-06 | 13G | MoonLake Immunotherapeutics MLTX | Merck Healthcare KGaA | 3,330,231 8.300% | 3,330,231 (New Position) | Filing History |
| 2022-04-18 4:49 pm Purchase | 2022-04-05 | 13D | MoonLake Immunotherapeutics MLTX | BIOTECHNOLOGY VALUE FUND L P | 21,751,284 58.900% | 21,751,284 (New Position) | Filing History |
| 2022-02-14 2:35 pm Sale | 2021-12-31 | 13G | Helix Acquisition Corp. HLXA | T. Rowe Price Associates, Inc. | 746,862 6.200% | -40,923 (-5.19%) | Filing History |